Quantcast

Latest Biologic Stories

2014-04-16 08:32:44

U.S. Institutional Investors Lead Oversubscribed Round To Advance Monoclonal Antibody Clinical Programs For Companion Animal Health MELBOURNE, Australia, April 16, 2014 /PRNewswire/ -- Nexvet Biopharma, a leading veterinary biologic drug developer, today announced the closing of its US$31.5 million Series B round of financing. Top-tier U.S.-based institutional investors Farallon Capital Management, LLC, Adage Capital Partners, L.P, Foresite Capital, and Tavistock Life Sciences...

2014-04-14 12:33:08

ROCKVILLE, Md., April 14, 2014 Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and other diseases, announced today the formation of a Clinical Advisory Board (CAB) to support development of the Company's constipation-predominant irritable bowel syndrome (C-IBS) program. The Company also announced that pioneering gastroenterologist and lead investigator for the C-IBS...

2014-04-11 23:01:51

Transparency Market Research Report Added "Biosimilar And Follow-On Biologics Market - Global Industry Size, Share, Trends, Analysis And Forecasts 2012 - 2018" to its database. Browse Full Report - http://www.transparencymarketresearch.com/biosimilar-and-follow-on-biologics-market.html. Albany, New York, USA (PRWEB) April 11, 2014 There is a rising demand for low cost biological drugs. Commercial and regulatory developments are taking the follow-on biologics market to new...

2014-04-10 23:02:16

Transparency Market Research Report added "Global Biological Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" to its database. Browse full report: http://www.transparencymarketresearch.com/biological-drugs-market.html. (PRWEB) April 10, 2014 Biological drugs are biological medical products whose active drug substance is extracted by using living organism. The active substance is derived from living organism by the usage of...

2014-04-09 23:02:52

Transparency Market Research Report Added "Biosimilars Market - Global And China Forecast, Share, Size, Growth And Industry Analysis 2010 - 2017" to its database. Browse Full Report: http://www.transparencymarketresearch.com/biosimilars-market.html. Albany, New York USA (PRWEB) April 09, 2014 Biosimilars or follow-on biologics are copies of biological drugs (biopharmaceuticals). Biosimilars provide significant cost saving to both the users and the industry, hence the adoption of...

2014-04-09 08:29:57

DUBLIN, April 9, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/stldww/global_psoriasis) has announced the addition of the "Global Psoriasis Therapeutics Market" [http://www.researchandmarkets.com/research/stldww/global_psoriasis ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The analysts forecast the Global Psoriasis Therapeutics market to grow at a CAGR of 4.06 percent over the...

2014-04-08 23:02:54

New research report “Biosimilar Index: Tracking the Global Biosimilar Pipeline” worked out by FirstWord is now available at MarketPublishers.com London, UK (PRWEB) April 08, 2014 At present, biosimilars and non-comparable biologics (NCBs) are being developed across thirteen discreet therapy areas. There exist around 40 biosimilar and NCB programmes currently in Phase III trials. Moreover, it is known that there are fifteen biosimilar and NCB versions of bevacizumab (Avastin, Roche)...

2014-04-08 12:31:33

ROCKVILLE, Md., April 8, 2014 /PRNewswire/ -- Biologics development and manufacturing services provider Omnia Biologics, Inc. (Omnia) (Rockville, MD) today announced that Karen Hughes has joined the Omnia team as Senior Director of Quality Assurance and Quality Control. Over the course of her nearly 23 year career in quality assurance, she has held quality positions of increasing responsibility in the manufacturing of pioneering pharmaceutical and biologic products. Karen worked for...

2014-04-08 08:30:44

ST. LOUIS, April 8, 2014 /PRNewswire/ -- ISTO Technologies, Inc. ("ISTO," the "Company"), a privately-held regenerative medicine company applying its proprietary platform technologies to orthopedic and spine applications, has appointed Phillip W. Kuhn, a medical technology executive with over three decades of industry experience, as the Company's Chief Commercial Officer. In this newly created role, Mr. Kuhn will oversee ISTO's commercial strategy, including the execution of...

2014-04-07 08:31:02

CARLSBAD, Calif., April 7, 2014 /PRNewswire/ -- Advanced Biologics announced today that they will be showcasing their most recent peer-reviewed published data at the American Academy of Neurosurgeons (AANS) meeting this week in San Francisco, CA. In the study titled Clinical Evaluation of Allogeneic Growth Factor in Cervical Spine Fusion, a retrospective analysis was conducted of one hundred and forty consecutive patients (228 levels) that had undergone cervical spine fusions using...


Word of the Day
kenspeckle
  • Having so marked an appearance as easily to be recognized.
This word may come from the Swedish 'kanspak,' quick at recognizing persons or things, or else from confusion with 'conspicuous.'